Phaseline

Companies › Chengdu Origen Biotechnology

Chengdu Origen Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 4 Phase 1; Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KH631
AAV vector-based gene therapy expressing anti-VEGF protein
VEGFAPhase 1Age-Related Macular DegenerationDec 2026
KH658
AAV vector delivering anti-VEGF protein
VEGFAPhase 1Age-related Macular Degeneration; Age-Related Macular DegenerationDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06458595KH658Phase 1Age-related Macular DegenerationOphthalmologyDec 2026
NCT05672121KH631Phase 1Age-Related Macular DegenerationOphthalmologyDec 2026
NCT06825858KH658Phase 1Age-Related Macular DegenerationOphthalmologyJan 2027
NCT05657301KH631Phase 1Age-Related Macular DegenerationOphthalmologySep 2027

Targets

VEGFA (2)

Companies with the same targets

Roche Jiangsu Simcere Pharmaceutical Biotheus AstraZeneca Prestige Biopharma Avirmax Biopharma Eli Lilly 4D Molecular Therapeutics PPD Development, LP Shanghai Henlius Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.